WallStSmart

Evotec SE ADR (EVO)vsTakeda Pharmaceutical Co Ltd ADR (TAK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Takeda Pharmaceutical Co Ltd ADR generates 653261% more annual revenue ($4.69T vs $718.32M). TAK leads profitability with a 0.9% profit margin vs -25.2%. TAK appears more attractively valued with a PEG of 0.48. TAK earns a higher WallStSmart Score of 54/100 (C-).

EVO

Hold

42

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 7.0Quality: 5.5
Piotroski: 5/9Altman Z: 0.38

TAK

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 5.5Value: 5.7Quality: 4.5
Piotroski: 3/9Altman Z: 1.05
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EVOUndervalued (+89.5%)

Margin of Safety

+89.5%

Fair Value

$33.26

Current Price

$1.32

$31.94 discount

UndervaluedFair: $33.26Overvalued

Intrinsic value data unavailable for TAK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVO1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

TAK4 strengths · Avg: 9.8/10
PEG RatioValuation
0.4810/10

Growing faster than its price suggests

Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Free Cash FlowQuality
$212.65B10/10

Generating 212.6B in free cash flow

Market CapQuality
$68.40B9/10

Large-cap with strong market position

Areas to Watch

EVO4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$600.61M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-28.6%2/10

ROE of -28.6% — below average capital efficiency

TAK4 concerns · Avg: 2.8/10
Return on EquityProfitability
5.2%3/10

ROE of 5.2% — below average capital efficiency

Profit MarginProfitability
0.9%3/10

0.9% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
305.9x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : EVO

The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.

Bull Case : TAK

The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.48 suggests the stock is reasonably priced for its growth.

Bear Case : EVO

The primary concerns for EVO are Revenue Growth, EPS Growth, Market Cap.

Bear Case : TAK

The primary concerns for TAK are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 305.9x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

EVO profiles as a turnaround stock while TAK is a value play — different risk/reward profiles.

EVO carries more volatility with a beta of 1.31 — expect wider price swings.

TAK is growing revenue faster at 6.7% — sustainability is the question.

TAK generates stronger free cash flow (212.6B), providing more financial flexibility.

Bottom Line

TAK scores higher overall (54/100 vs 42/100). EVO offers better value entry with a 89.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evotec SE ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.

Takeda Pharmaceutical Co Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?